OCUP - Ocuphire extends IP rights for lead candidate with new U.S. patent

• Ophthalmology-focused Ocuphire Pharma ( NASDAQ: OCUP ) announced on Wednesday the issuance of a new U.S. patent for its lead candidate Nyxol eye drops that could extend the IP rights for the eye disease candidate.
• Nyxol is a once-daily, eye drop formulation of phentolamine mesylate targeted at multiple eye indications including reversal of pharmacologically induced mydriasis (RM).
• The U.S. Patent No. 11,400,077, relating to methods for treating mydriasis using phentolamine mesylate,e extends the patent protection for Nyxol into 2039 from 2034, the company said. The patent is eligible for listing in the FDA Orange Book.
• The company is on track to submit a New Drug Application for Nyxol in late 2022 to the FDA targeting patients with RM and expects to launch the drug in 2H 2023, subject to approval.
• In March, Ocuphire ( OCUP ) announced that its second Phase 3 trial for Nyxol in RM met its main goal.

For further details see: